Characteristics of the coexistence of melanoma and renal cell carcinoma

Cancer

Volumn 116, Issue 24, 2010, Pages 5716-5724

  Maubec, Eve ^a,b   Chaudru, Valérie ^a,c,d   Mohamdi, Hamida ^a,d,e   Grange, Florent ^f   Patard, Jean Jacques ^g   Dalle, Stéphane ^h   Crickx, Béatrice ^b   Paillerets, Brigitte Bressac De ^a,i   Demenais, Florence ^a,d,e   Avril, Marie Françoise ^j  

^a National Institute of Health and Medical Research   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^d Jean Dausset Foundation Center for the Study of Human Polymorphisms   (France)

^e UNIVERSITÉ PARIS DIDEROT   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j université Paris Cité   (France)

more..

Author keywords

familial melanoma; genetic predisposition; melanoma; multiple primary neoplasms; renal cell carcinoma

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE 2A GENE; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HAIR COLOR; HUMAN; KIDNEY CARCINOMA; MALE; MELANOMA; MULTIPLE CANCER; NEVUS; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO; SKIN CANCER; SKIN COLOR;

ADULT; AGED; CARCINOMA, RENAL CELL; CYCLIN-DEPENDENT KINASE 4; FAMILY HEALTH; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; RISK FACTORS; SKIN NEOPLASMS;

EID: 78650103649     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25562     Document Type: Article

References (43)

1. Grange F,. [Epidemiology of cutaneous melanoma: descriptive data in France and Europe]. Ann Dermatol Venereol. 2005; 132: 975-982.
2. Tucker MA,. Melanoma epidemiology. Hematol Oncol Clin North Am. 2009; 23: 383-395.
3. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002; 94: 894-903.
4. Meyle KD, Guldberg P,. Genetic risk factors for melanoma. Hum Genet. 2009; 126: 499-510.
5. Gudbjartsson DF, Sulem P, Stacey SN, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet. 2008; 40: 886-891.
6. Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies 3 loci associated with melanoma risk. Nat Genet. 2009; 41: 920-925.
7. Belot A, Grosclaude P, Bossard N, et al. Cancer incidence and mortality in France over the period 1980-2004. Rev Epidemiol Sante Public. 2008: 56; 159-175.
8. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE,. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007; 166: 932-940.
9. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC,. Family history and risk of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2001; 10: 1001-1004.
10. Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009; 18: 801-807.
11. Pavlovich CP, Schmidt LS,. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer. 2004; 4: 381-393.
12. Bhatia S, Estrada-Batres L, Maryon T, Bogue M, Chu D,. Second primary tumors in patients with cutaneous malignant melanoma. Cancer. 1999; 86: 2014-2020.
13. Wassberg C, Thorn M, Yuen J, Ringborg U, Hakulinen T,. Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer. 1996; 73: 255-259. (Pubitemid 26028343)
14. Bradford PT, Freedman DM, Goldstein AM, Tucker MA,. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010; 146: 265-272.
15. Rabbani F, Grimaldi G, Russo P,. Multiple primary malignancies in renal cell carcinoma. J Urol. 1998; 160: 1255-1259. (Pubitemid 29480492)
16. Beisland C, Talleraas O, Bakke A, Norstein J,. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int. 2006; 97: 698-702.
17. Wilson RT, Silverman DK, Fraumeni JF, Curtis RE,. New malignancies following cancer of the urinary tract. In:, Curtis RE, Freedman DM, Ron E, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ. No. 05-5302. Bethesda, Md: National Cancer Institute; 2006: 285-312.
18. Crocetti E, Guzzinati S, Paci E, et al. The risk of developing a second, different, cancer among 14,560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries). Melanoma Res. 2008; 18: 230-234.
19. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M,. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001; 145: 981-985.
20. Wu YH, Kim GH, Wagner JD, Hood AF, Chuang TY,. The association between malignant melanoma and noncutaneous malignancies. Int J Dermatol. 2006; 45: 529-534.
21. Freedman DM, Miller BA, Tucker MA,. New malignancies following melanoma of the skin, eye melanoma, and non-melanoma eye cancer. In:, Curtis RE, Freedman DM, Tucker P, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ. No. 05-5302. Bethesda, Md: National Cancer Institute; 2006: 339-362.
22. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997; 183: 131-133.
23. Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumors. 7th ed. New York: Wiley-Blackwell; 2009.
24. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27: 6199-6206.
25. Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst. 2004; 96: 785-795.
26. Grange F, Chompret A, Guilloud-Bataille M, et al. Comparison between familial and nonfamilial melanoma in France. Arch Dermatol. 1995; 131: 1154-1159.
27. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004; 22: 3316-3322.
28. Laud K, Marian C, Avril MF, et al. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet. 2006; 43: 39-47.
29. Kannengiesser C, Brookes S, del Arroyo AG, et al. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. Hum Mutat. 2009; 30: 564-574.
30. Lesueur F, de Lichy M, Barrois M, et al. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer. 2008; 99: 364-370.
31. Patard JJ, Leray E, Cindolo L, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol. 2004; 172: 858-862.
32. Czene K, Hemminki K,. Kidney cancer in the Swedish Family Cancer Database: familial risks and second primary malignancies. Kidney Int. 2002; 61: 1806-1813.
33. Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from 3 continents. J Med Genet. 2007; 44: 99-106.
34. FitzGerald MG, Harkin DP, Silva-Arrieta S, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996; 93: 8541-8545.
35. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999; 7: 267-273.
36. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
37. Bretheau D, Koutani A, Lechevallier E, Coulange C,. A French national epidemiologic survey on renal cell carcinoma. Oncology Committee of the Association Francaise d'Urologie. Cancer. 1998; 82: 538-544.
38. Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N,. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations. Cancer. 1997; 79: 275-283.
39. National Cancer Institute. SEER Stat Fact Sheets: Melanoma of the Skin. Bethesda, Md: National Cancer Institute; 2009. Accessed May 1, 2010.
40. Beisland C, Medby PC, Beisland HO,. Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. Scand J Urol Nephrol. 2002; 36: 414-418.
41. Florell SR, Boucher KM, Garibotti G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol. 2005; 23: 7168-7177.
42. Gerstenblith MR, Shi J, Landi MT,. Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis [published online ahead of print June 14, 2010]. Pigment Cell Melanoma Res. 2010. Accessed August 13, 2010.
43. Lee CT, Katz J, Fearn PA, Russo P,. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002; 7: 135-140.